First in Human Study of the DaVingi™ TR System in the Treatment of Patients With Functional Tricuspid Regurgitation

Cardiac Implants

Status

Unknown

Conditions

Functional Tricuspid Regurgitation (TR)

Treatments

Device: DaVingiTR System

Study type

Interventional

Funder types

Industry

Identifiers

NCT03700918

CLP-001

Details and patient eligibility

About

The DaVingi™ System is a percutaneous trans-catheter device delivered using right heart catheterization through the right internal jugular vein. The DaVingi™ System is designed for performing ring annuloplasty by using a Ring Delivery System to place a complete, flexible fabric ring around the annulus of the atrial side of the tricuspid valve. Fluoroscopy and echocardiography are used to monitor the ring placement procedure.

Full description

The annuloplasty ring is a small multi-element ring, consisting of an outer fabric layer, a pre-set stakes array and internal adjustment cord that can be adjusted at a later stage after the outer layer of the ring and stakes are encapsulated in new tissue growth. Once implanted, the ring is designed to serve as a foundation for promoting new annular tissue growth, effectively growing a new adjustable annulus around the valve.

the study has been approved by Institutional Review Boards and Competent Authorities in Czech Republic, France and Israel.

Enrollment

15 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Severe tricuspid regurgitation as defined by American Society of Echocardiography.
Symptoms of right ventricular failure despite appropriate medical therapy.
Multidisciplinary heart team (minimum of three physicians, including cardiology and cardiac surgery representatives) recommends tricuspid annuloplasty.
≥18 years old at time of enrollment.
LVEF ≥ 30% within 45 days prior to index implant procedure.
PASP < 70 mmHg via right heart catheterization (subject at rest) within 90 days prior to index implant procedure.
Right Ventricle TAPSE ≥ 13 mm within 45 days prior to index implant procedure.
Tricuspid valve annular diameter ≥ 40 mm as measured by baseline transthoracic echocardiography in the 4 chamber view within 45 days prior to index implant procedure.
Subject has provided written informed consent.
Subject agrees to comply with all required post-procedure follow-up visits, including device adjustment.

Exclusion criteria

Acutely decompensated heart failure (i.e. hemodynamically unstable or on IV inotropes).
Severe Right Ventricle dysfunction.
Primary tricuspid pathology (e.g. rheumatic, congenital, infective, etc.).
Previous tricuspid valve repair or replacement.
Transvalvular pacemaker or defibrillator lead is present.
Severe left-sided valve disease.
Right-sided intra-cardiac mass, thrombus or vegetation is present.
Inability to properly guide the index implant procedure using Trans-esophagus echocardiography (e.g. acoustic window not adequate).
Subject requires chronic dialysis or renal replacement therapy.
MI or known unstable angina within the 30-days prior to the implant index procedure.
CVA within 3 months prior to index implant procedure.
Bleeding disorders, active peptic ulcer or GI bleed.
Contraindication to anticoagulation or antiplatelet medication, based on investigator's opinion.
Chronic oral steroid or immunomodulator use (≥ 6 months) or other condition that could impair healing response (e.g. cardiac sarcoidosis or other chronic inflammatory disease).
Any condition that, in the opinion of the investigator, may render the subject unable to complete the study (life expectancy < 1 year), or lead to difficulties for subject compliance with study requirements.
Subject is enrolled in another investigational study which has not completed the required primary endpoint follow-up period (Note: patients involved in a long-term surveillance phase of another study are eligible for this study).
Female patients who are pregnant or lactating.